SCHEMBL5582212

SCHEMBL5582212

CNc1ncc2c(-c3cccc(Cl)c3)cc(-c3ccc(C(=O)O)cc3)c(OC)c2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 9/20 0.49
CSNK2A2 P19784 5/20 0.49
CSNK2B P67870 5/20 0.49
MAP4K4 O95819 1/20 0.45
PTK2 Q05397 1/20 0.42
ADORA1 P30542 2/20 0.41
PDE4D Q08499 3/20 0.41
PDE4A P27815 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4B Q07343 2/20 0.39
CAMK2D Q13557 1/20 0.39
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38
TUBB4B P68371 1/20 0.38
TUBB3 Q13509 1/20 0.38
TUBB2A Q13885 1/20 0.38
TUBB8 Q3ZCM7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5581995 0.94 CSNK2A1 (0.50) CSNK2A1CSNK2A2CSNK2BMAP4K4PTK2
SCHEMBL5582255 0.92 CSNK2A1 (0.43) CSNK2A1CSNK2A2CSNK2BMAP4K4PTK2
SCHEMBL5582010 0.91 CSNK2A2 (0.47) CSNK2A1CSNK2A2CSNK2BMAP4K4PTK2
SCHEMBL5582330 0.91 CSNK2A1 (0.48) CSNK2A1CSNK2A2CSNK2BMAP4K4PTK2
SCHEMBL5582194 0.91 CSNK2A1 (0.48) CSNK2A1CSNK2A2CSNK2BMAP4K4ADORA1
SCHEMBL5581820 0.90 ADORA1 (0.43) CSNK2A1CSNK2A2CSNK2BMAP4K4ADORA1
SCHEMBL5582053 0.90 CSNK2A1 (0.49) CSNK2A1CSNK2A2CSNK2BMAP4K4PTK2
SCHEMBL5581541 0.90 CSNK2A1 (0.47) CSNK2A1CSNK2A2CSNK2BMAP4K4PTK2
SCHEMBL5582093 0.90 CSNK2A1 (0.49) CSNK2A1CSNK2A2CSNK2BMAP4K4PTK2
SCHEMBL5582245 0.90 CSNK2A1 (0.51) CSNK2A1CSNK2A2CSNK2BMAP4K4PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225308-A1 2-Amino Quinazoline Derivative KYOWA HAKKO KOGYO CO.,LTD. (JP) 2007-09-27 US disclosed
EP-1726584-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225308-A1 2-Amino Quinazoline Derivative AGTR2, ABL1, AGTR1 CSNK2A1 602/4885CSNK2A2 467/4885CSNK2B 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.